title: Technology evaluation: desmoteplase, PAION/Forest.
abstract: PAION GmbH, under license from Schering AG, is developing desmoteplase, a recombinant form of the anticlotting salivary plasminogen activator of the vampire bat Desmodus rotundus (DSPAalpha-1), for the potential treatment of acute ischemic stroke. The drug is currently undergoing phase II clinical trials.
authors.affiliation: Ferme des Cazalères, 09350 Daumazan sur Arize, France. tony.debens@wanadoo.fr
authors.forename: Tony
authors.initials: T
authors.lastname: Debens
mesh_terms: D000818:Animals; D002545:Brain Ischemia / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy; D010330:Patents as Topic; D010960:Plasminogen Activators / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D011655:Pulmonary Embolism / Q000188:drug therapy; D013329:Structure-Activity Relationship
chemical_list: C069588:salivary plasminogen activator alpha 1, Desmodus rotundus; D010960:Plasminogen Activators